Manage Your Liver
Q:

WHO’s latest Hepatitis strategies are focused on preventing and reducing damage caused by hepatitis, what should hepatitis B and C patients do?

A:

According to the latest data provided by the World Health Organization, there are 400 million people living with hepatitis B and C worldwide; 1.4 million die due to these infections every year and many more become newly infected. [1] In recent years, WHO launched a range of new strategies and guidelines for this serious global problem. In 2014 and 2015, for the first time, WHO introduced countermeasures guidance to countries around the world on hepatitis C and B respectively. In the guidelines, WHO clearly presented a 3-part prevention plan which included (not limited to) the following [2]:

 

  • immunization with the hepatitis A and B vaccines to prevent co-infection from these hepatitis viruses to protect the liver;
  • early and appropriate medical management including antiviral therapy if appropriate; and
  • regular monitoring for early diagnosis of chronic liver disease (including liver cirrhosis and liver cancer)

 

Another document published by WHO – “Prevention and Control of Viral Hepatitis Infection” further states that our goals should be to reduce morbidity and mortality due to viral hepatitis, improve the care of patients with viral hepatitis and improve the support provided by our society to hepatitis patients. [3] This implies that WHO is recommending hepatitis patients to think further; other than just killing the virus, focus should also be put on these aspects: how to avoid the spread of the virus, how to reduce liver damage caused by the virus, how to prevent liver cirrhosis and liver cancer, and how to improve activity and ability to work.

 

In a sense, it also shows that WHO does not consider the effects of current treatment options on viral hepatitis B and C to be ideal. These treatments advocated by various professionals failed to address the hazards of viral hepatitis B and C, prevent new infections, and lower the number of patients, or the number of deaths caused by the disease. However, countries around the world have paid a very high price because of these ineffective methods.

 

For now, the general consensus is that our focus should be put on: preventing new infections and reducing the spread of the virus, advocating and seeking ways to reduce inflammation and damage caused by hepatitis, preventing inflammation in the liver to reduce risks of liver cirrhosis and liver cancer, and improving the everyday ability and life skills of hepatitis patients.

 

In this context, our liver health maintenance methods that we advocate and promote are very much in line with the proposal and conclusions by WHO.

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
A:
Hepatitis C is a wide spread and deadly disease affecting an estimated of 3.5 million Americans.   Treatment for hepatitis C has evolved over the years, going from highly toxic drugs involving injections with horrible side effects, to medications with minimal side effects. Success rate of treatment options has also improved greatly Although the high price tag of the new DAA treatment is controversial, it has undoubtedly helped to cure many hepatitis C patients.
A:
ALT (Alanine Aminotransferase / SGPT) is an enzyme that is mainly found in liver cells. The level of ALT in our bloodstream is the primary indicator of liver health. Multiple studies have demonstrated that the presence of an elevated ALT level is associated with increased liver-related mortality.   New normal ALT level issued The American College of Gastroenterology (ACG) recently issued a new Practice Guideline that aims to offer a framewor
Hit Questions
A:
YHK has significant effect in stopping liver inflammation; it can enhance the recovery of liver health and protect liver cells. Those who have experienced YHK often have these questions in mind: Why is YHK so different from other liver medicines and supplements? Why is it possible to have such unprecedented effects? The answer seems magical, but in fact, it is not complicated - Because YHK possesses a perfect balance.   To explain this, we must first point out that YH
A:
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
A:
Hepatitis C is a wide spread and deadly disease affecting an estimated of 3.5 million Americans.   Treatment for hepatitis C has evolved over the years, going from highly toxic drugs involving injections with horrible side effects, to medications with minimal side effects. Success rate of treatment options has also improved greatly Although the high price tag of the new DAA treatment is controversial, it has undoubtedly helped to cure many hepatitis C patients.
A:
“It isn't fat but rather fibrosis that drives disease progression in people with advanced non-alcoholic steatohepatitis (NASH).”   NASH is one of the most prevalent liver diseases nowadays. NASH is related to non-alcoholic fatty liver disease (NAFLD) which is characterized by the buildup of fat in the liver. Although it is normal to have some fat in the liver, some people might develop inflammation because of this fat accumulation, this is cal
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us